A Phase 1 interventional study of Rosuvastatin and Metformin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers want to learn about calderasib when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with and without calderasib
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
- Has (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rosuvastatin plus metformin
Drug: Rosuvastatin · Drug: Metformin
Participants will receive rosuvastatin plus metformin plus calderasib
Drug: Rosuvastatin · Drug: Metformin · Drug: Calderasib
Oral tablet
Oral tablet
Oral tablet
Also known as: MK-1084
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Rosuvastatin
Blood samples will be collected at multiple time points to determine the AUC0-inf of rosuvastatin
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
Maximum Plasma Concentration (Cmax) of Rosuvastatin
Blood samples will be collected at multiple time points to determine the Cmax of rosuvastatin
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
AUC0-inf of Metformin
Blood samples will be collected at multiple time points to determine the AUC0-inf of metformin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Area Under the Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of Rosuvastatin
Blood samples will be collected at multiple time points to determine the AUC0-last of rosuvastatin
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
Area Under the Curve From Time 0 to 24 Hours (AUC0-24hrs) of Rosuvastatin
Blood samples will be collected at multiple time points to estimate AUC0-24
Time frame: Day 1: Predose and at designated timepoints up to 24 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin
Blood samples will be collected at multiple time points to estimate Tmax
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
Day 1: Apparent Terminal Half-life (t1/2) of Rosuvastatin
Blood samples will be collected at multiple time points to estimate t1/2
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
Apparent Clearance (CL/F) of Rosuvastatin
Blood samples will be collected at multiple time points to estimate CL/F
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Rosuvastatin
Blood samples will be collected at multiple time points to estimate Vz/F
Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose
AUC0-last of Metformin
Blood samples will be collected at multiple time points to estimate AUC0-last
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-24hrs of Metformin
Blood samples will be collected at multiple time points to estimate AUC0-24
Time frame: Day 1: Predose and at designated timepoints up to 24 hours post-dose
Cmax of Metformin
Blood samples will be collected at multiple time points to estimate Cmax
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Tmax of Metformin
Blood samples will be collected at multiple time points to estimate Tmax
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
t1/2 of Metformin
Blood samples will be collected at multiple time points to estimate t1/2
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
CL/F of Metformin
Blood samples will be collected at multiple time points to estimate CL/F
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Vz/F of Metformin
Blood samples will be collected at multiple time points to estimate Vz/F
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-inf of Calderasib
Blood samples will be collected at multiple time points to estimate AUC0-inf
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-last of Calderasib
Blood samples will be collected at multiple time points to estimate AUC0-last
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-24hrs of Calderasib
Blood samples will be collected at multiple time points to estimate AUC0-24
Time frame: Day 1: Predose and at designated timepoints up to 24 hours post-dose
Cmax of Calderasib
Blood samples will be collected at multiple time points to estimate Cmax
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Plasma Concentration at 24 Hours (C24) of Calderasib
Blood samples will be collected to estimate C24
Time frame: 24 hours post-dose
Tmax of Calderasib
Blood samples will be collected at multiple time points to estimate Tmax
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
t1/2 of Calderasib
Blood samples will be collected at multiple time points to estimate t1/2
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
CL/F of Calderasib
Blood samples will be collected at multiple time points to estimate CL/F
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Vz/F of Calderasib
Blood samples will be collected at multiple time points to estimate Vz/F
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Amount of Metformin Excreted Unchanged in Urine (Ae)
Urine samples will be collected at multiple time points to estimate Ae
Time frame: Day 1: Predose and at designated timepoints up to 48 hours post-dose
Fraction of Metformin Excreted Unchanged in Urine (Fe)
Urine samples will be collected at multiple time points to estimate Fe
Time frame: Day 1: Predose and at designated timepoints up to 48 hours post-dose
Renal Clearance of Metformin (CLr)
Urine samples will be collected at multiple time points to estimate CLr
Time frame: Day 1: Predose and at designated timepoints up to 48 hours post-dose
Number of Participants Who Experience an Adverse Avent (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.
Time frame: Up to approximately 28 days after first dose
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.
Time frame: Up to approximately 14 days after first dose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2025 to primary completion in Dec 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Metformin